CA3218448A1 - Combination treatment methods - Google Patents

Combination treatment methods Download PDF

Info

Publication number
CA3218448A1
CA3218448A1 CA3218448A CA3218448A CA3218448A1 CA 3218448 A1 CA3218448 A1 CA 3218448A1 CA 3218448 A CA3218448 A CA 3218448A CA 3218448 A CA3218448 A CA 3218448A CA 3218448 A1 CA3218448 A1 CA 3218448A1
Authority
CA
Canada
Prior art keywords
bupropion
nicotine
subject
zonisamide
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218448A
Other languages
English (en)
French (fr)
Inventor
Jed E. Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rose Research Center LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3218448A1 publication Critical patent/CA3218448A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/32—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by acyclic compounds
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3218448A 2021-05-11 2022-05-10 Combination treatment methods Pending CA3218448A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187001P 2021-05-11 2021-05-11
US63/187,001 2021-05-11
PCT/US2022/028504 WO2022240819A1 (en) 2021-05-11 2022-05-10 Combination treatment methods

Publications (1)

Publication Number Publication Date
CA3218448A1 true CA3218448A1 (en) 2022-11-17

Family

ID=84028804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218448A Pending CA3218448A1 (en) 2021-05-11 2022-05-10 Combination treatment methods

Country Status (7)

Country Link
US (1) US20250073186A1 (https=)
EP (1) EP4337181A4 (https=)
JP (1) JP2024517335A (https=)
CN (1) CN117693335A (https=)
AU (1) AU2022273620A1 (https=)
CA (1) CA3218448A1 (https=)
WO (1) WO2022240819A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4593814A1 (en) * 2022-09-26 2025-08-06 Rose Research Center, LLC Combination for use in a method of preventing weight gain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物
US20070212428A1 (en) * 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
KR20170077291A (ko) * 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지

Also Published As

Publication number Publication date
CN117693335A (zh) 2024-03-12
JP2024517335A (ja) 2024-04-19
AU2022273620A1 (en) 2023-11-30
US20250073186A1 (en) 2025-03-06
EP4337181A4 (en) 2025-04-16
EP4337181A1 (en) 2024-03-20
WO2022240819A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
Henningfield et al. Pharmacotherapy for Nicotine Dependence 1
Schneider et al. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments
Foulds et al. Advances in pharmacotherapy for tobacco dependence
Fagerström et al. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?
Tønnesen et al. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial
Chapman et al. A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes
King et al. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences
Schuh et al. Nicotine nasal spray and vapor inhaler: abuse liability assessment
Casella et al. Therapeutic advances in the treatment of nicotine addiction: present and future
Fant et al. Nicotine replacement therapy
Cornuz Smoking cessation interventions in clinical practice
Glover et al. A multicenter phase 3 trial of lobeline sulfate for smoking cessation
JP2022548876A (ja) 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物
US20250073186A1 (en) Combination treatment methods
Frishman Smoking cessation pharmacotherapy
Schneider et al. Comparative testing of 5 nicotine systems: initial use and preferences
Stack Smoking cessation: an overview of treatment options with a focus on varenicline
Bittoun A combination nicotine replacement therapy (NRT) algorithm for hard-to-treat smokers
Talwar et al. Pharmacotherapy of tobacco dependence
Schneider et al. Preferences among four combination nicotine treatments
Bolliger et al. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy
Suchanek Hudmon et al. Current approaches to pharmacotherapy for smoking cessation
EP4593814A1 (en) Combination for use in a method of preventing weight gain
JP2024517335A5 (https=)
Shiffman et al. Nicotine delivery systems: How far has technology come?

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502